Citations (70)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Barbara Rossetti, Francesca Montagnani & Andrea De Luca. (2018) Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opinion on Pharmacotherapy 19:7, pages 713-738.
Read now
Read now
Vicente Soriano, Jose Vicente Fernandez-Montero, Laura Benitez-Gutierrez, Carmen de Mendoza, Ana Arias, Pablo Barreiro, José M. Peña & Pablo Labarga. (2017) Dual antiretroviral therapy for HIV infection. Expert Opinion on Drug Safety 16:8, pages 923-932.
Read now
Read now
Maile Y. Karris, Sonia Jain, Tyler R.C. Day, Josué Pérez-Santiago, Miguel Goicoechea, Michael P. Dubé, Xiaoying Sun, Celsa Spina, Eric S. Daar, Richard H. Haubrich & Sheldon Morris. (2017) HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen. HIV Clinical Trials 18:2, pages 67-74.
Read now
Read now
Lars G. Hemkens, Hannah Ewald, Marilia Santini-Oliveira, Julian-Emanuel Bühler, Danielle Vuichard, Stefan Schandelmaier, Marcel Stöckle, Matthias Briel & Heiner C. Bucher. (2015) Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis. HIV Clinical Trials 16:5, pages 178-189.
Read now
Read now
Andrea Calcagno, Antonio D’Avolio & Stefano Bonora. (2015) Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients. Expert Opinion on Drug Metabolism & Toxicology 11:7, pages 1167-1176.
Read now
Read now
Eva Van den Eynde & Daniel Podzamczer. (2014) Switch strategies in antiretroviral therapy regimens. Expert Review of Anti-infective Therapy 12:9, pages 1055-1074.
Read now
Read now
James Nuttall, Tammy Meyers & Brian Eley. (2013) Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents. Pediatric Health, Medicine and Therapeutics 4, pages 75-87.
Read now
Read now
Christoph Stephan. (2012) Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature. Expert Opinion on Pharmacotherapy 13:16, pages 2355-2367.
Read now
Read now
Articles from other publishers (62)
Liu Hui, Han Xiaoxu, Wang Yuqi, Wang Peng, Wang Xin, Yi Yunyun & Li Xin. (2022) Effectiveness and Safety Analysis of PIs/r Based Dual Therapy in Treatment-Naïve, HIV/AIDS Patients: A Network Meta Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 13.
Crossref
Crossref
Ekhlass Uddin, Raisul Islam, Ashrafuzzaman, Nur Amin Bitu, Md. Saddam Hossain, ABM Nazmul Islam, Ali Asraf, Faruk Hossen, Ranjan K Mohapatra & Md. Kudrat-E-Zahan. (2021) Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application. Current Drug Research Reviews 13:3, pages 184-202.
Crossref
Crossref
Mariantonietta Pisaturo, Lorenzo Onorato, Antonio Russo, Salvatore Martini, Paolo Chiodini, Simona Signoriello, Paolo Maggi & Nicola Coppola. (2021) Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysis. Clinical Microbiology and Infection 27:1, pages 28-35.
Crossref
Crossref
Yinqiu Huang, Xiaojie Huang, Hui Chen, Hao Wu & Yaokai Chen. (2019) Efficacy and Safety of Raltegravir-Based Dual Therapy in AIDS Patients: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 10.
Crossref
Crossref
S Gallien, M Massetti, P Flandre, H Leleu, D Descamps & E Lazaro. (2018) Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis. HIV Medicine 19:8, pages 559-571.
Crossref
Crossref
Carlo Perrone, Andri Rauch, Hansjakob Furrer, Markus Hug & Gilles Wandeler. (2018) Fewer pills do not mean fewer drug–drug interactions. AIDS 32:5, pages 676-678.
Crossref
Crossref
C Orkin, JM Llibre, S Gallien, A Antinori, GMN Behrens & A Carr. (2018) Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence. HIV Medicine 19:1, pages 18-32.
Crossref
Crossref
James G Hakim, Jennifer Thompson, Cissy Kityo, Anne Hoppe, Andrew Kambugu, Joep J van Oosterhout, Abbas Lugemwa, Abraham Siika, Raymond Mwebaze, Aggrey Mweemba, George Abongomera, Margaret J Thomason, Philippa Easterbrook, Peter Mugyenyi, A Sarah Walker, Nicholas I Paton, E Agweng, P Awio, G Bakeinyaga, C Isabirye, U Kabuga, S Kasuswa, M Katuramu, F Kiweewa, H Kyomugisha, E Lutalo, D Mulima, H Musana, G Musitwa, V Musiime, M Ndigendawan, H Namata, J Nkalubo, P Ocitti Labejja, P Okello, P Olal, G Pimundu, P Segonga, F Ssali, Z Tamale, D Tumukunde, W Namala, R Byaruhanga, J Kayiwa, J Tukamushaba, S Abunyang, D Eram, O Denis, R Lwalanda, L Mugarura, J Namusanje, I Nankya, E Ndashimye, E Nabulime, D Mulima, O Senfuma, G Bihabwa, E Buluma, A Elbireer, D Kamya, M Katwere, R Kiggundu, C Komujuni, E Laker, E Lubwama, I Mambule, J Matovu, A Nakajubi, J Nakku, R Nalumenya, L Namuyimbwa, F Semitala, B Wandera, J Wanyama, H Mugerwa, E Ninsiima, T Ssenkindu, S Mwebe, L Atwine, H William, C Katemba, S Abunyang, M Acaku, P Ssebutinde, H Kitizo, J Kukundakwe, M Naluguza, K Ssegawa, Namayanja, F Nsibuka, P Tuhirirwe, M Fortunate, J Acen, J Achidri, A Amone, M Chamai, J Ditai, M Kemigisa, M Kiconco, C Matama, D Mbanza, F Nambaziira, M Owor Odoi, A Rweyora, G Tumwebaze, H Kalanzi, J Katabaazi, A Kiyingi, M Mbidde, M Mugenyi, P Okong, I Senoga, M Abwola, D Baliruno, J Bwomezi, A Kasede, M Mudoola, R Namisi, F Ssennono, S Tuhirwe, G Amone, J Abach, I Aciro, B Arach, P Kidega, J Omongin, E Ocung, W Odong, A Philliam, H Alima, B Ahimbisibwe, E Atuhaire, F Atukunda, G Bekusike, A Bulegyeya, D Kahatano, S Kamukama, J Kyoshabire, A Nassali, A Mbonye, T M Naturinda, Ndukukire, A Nshabohurira, H Ntawiha, A Rogers, M Tibyasa, S Kiirya, D Atwongyeire, A Nankya, C Draleku, D Nakiboneka, D Odoch, L Lakidi, R Ruganda, R Abiriga, M Mulindwa, F Balmoi, S Kafuma, E Moriku, A Reid, E Chidziva, G Musoro, C Warambwa, G Tinago, S Mutsai, M Phiri, S Mudzingwa, T Bafana, V Masore, C Moyo, R Nhema, S Chitongo, Robert Heyderman, Lucky Kabanga, Symon Kaunda, Aubrey Kudzala, Linly Lifa, Jane Mallewa, Mike Moore, Chrissie Mtali, George Musowa, Grace Mwimaniwa, Rosemary Sikwese, Milton Ziwoya, H Chimbaka B Chitete, S Kamanga, T Kayinga E Makwakwa, R Mbiya, M Mlenga, T Mphande, C Mtika, G Mushani, O Ndhlovu, M Ngonga, I Nkhana, R Nyirenda, P Cheruiyot, C Kwobah, W Lokitala Ekiru, M Mokaya, A Mudogo, A Nzioka, M Tanui, S Wachira, K Wools-Kaloustian, P Alipalli, E Chikatula, J Kipaila, I Kunda, S Lakhi, J Malama, W Mufwambi, L Mulenga, P Mwaba, E Mwamba, M Namfukwe, E Kerukadho, B Ngwatu, J Birungi, J Boles, A Burke, L Castle, S Ghuman, L Kendall, S Tebbs, J Whittle, H Wilkes, N Young, M Spyer, C Kapuya, F Kyomuhendo, D Kyakundi, N Mkandawire, S Mulambo, S Senyonjo, B Angus, A Arenas-Pinto, A Palfreeman, F Post, D Ishola, J Arribas, R Colebunders, M Floridia, M Giuliano, P Mallon, P Walsh, M De Rosa, E Rinaldi, I Weller, C Gilks, A Kangewende, S Lakhi, E Luyirika, F Miiro, S Ojoo, S Phiri, A Wapakabulo, T Peto, J Matenga, G Cloherty, J van Wyk, M Norton, S Lehrman, P Lamba, K Malik, J Rooney, W Snowden & J Villacian. (2018) Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. The Lancet Infectious Diseases 18:1, pages 47-57.
Crossref
Crossref
O. G. YURIN, N. N. LADNAYA & Z. K. SUVOROVA. (2017) SELECTION OF AN ANTIRETROVIRAL REGIMEN BASED ON THE RESISTANCE DATA. Medical Council:4, pages 63-66.
Crossref
Crossref
Christine Katlama, Jade Ghosn & Robert L. Murphy. (2017) Individualized antiretroviral therapeutic approaches. AIDS 31:8, pages 1065-1071.
Crossref
Crossref
Antonio Rivero, José Antonio Pérez-Molina, Antonio Javier Blasco, José Ramón Arribas, Manuel Crespo, Pere Domingo, Vicente Estrada, José Antonio Iribarren, Hernando Knobel, Pablo Lázaro, José López-Aldeguer, Fernando Lozano, Santiago Moreno, Rosario Palacios, Juan Antonio Pineda, Federico Pulido, Rafael Rubio, Javier de la Torre, Montserrat Tuset & Josep M. Gatell. (2017) Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades infecciosas y microbiologia clinica (English ed.) 35:2, pages 88-99.
Crossref
Crossref
Antonio Rivero, José Antonio Pérez-Molina, Antonio Javier Blasco, José Ramón Arribas, Manuel Crespo, Pere Domingo, Vicente Estrada, José Antonio Iribarren, Hernando Knobel, Pablo Lázaro, José López-Aldeguer, Fernando Lozano, Santiago Moreno, Rosario Palacios, Juan Antonio Pineda, Federico Pulido, Rafael Rubio, Javier de la Torre, Montserrat Tuset & Josep M. Gatell. (2017) Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas y Microbiología Clínica 35:2, pages 88-99.
Crossref
Crossref
M Jaeckle, P Khaykin, A Haberl, P De Leuw, G Schüttfort, C Stephan & T Wolf. (2016) Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice. International Journal of STD & AIDS 27:13, pages 1170-1179.
Crossref
Crossref
Ildefonso PulidoMiguel GenebatAna I. Alvarez-RiosRebeca S. De Pablo-BernalMohammed Rafii-El-Idrissi BenhniaYolanda M. PachecoEzequiel Ruiz-MateosManuel Leal. (2016) Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naive HIV-Infected Patients. Viral Immunology 29:8, pages 471-477.
Crossref
Crossref
Duncan Churchill, Laura Waters, Nadia Ahmed, Brian Angus, Marta Boffito, Mark Bower, David Dunn, Simon Edwards, Carol Emerson, Sarah Fidler, Martin Fisher, Rob Horne, Saye Khoo, Clifford Leen, Nicola Mackie, Neal Marshall, Fernando Monteiro, Mark Nelson, Chloe Orkin, Adrian Palfreeman, Sarah Pett, Andrew Phillips, Frank Post, Anton Pozniak, Iain Reeves, Caroline Sabin, Roy Trevelion, John Walsh, Ed Wilkins, Ian Williams & Alan Winston. (2016) British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Medicine 17, pages s2-s104.
Crossref
Crossref
Daniel Podzamczer & Arkaitz Imaz. (2016) Dual antiretroviral therapy: finding a place in the battle. The Lancet HIV 3:8, pages e335-e336.
Crossref
Crossref
Amit C Achhra, Gwamaka Mwasakifwa, Janaki Amin & Mark A Boyd. (2016) Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. The Lancet HIV 3:8, pages e351-e360.
Crossref
Crossref
Juan Berenguer, Antonio Rivero, Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, Bonaventura Clotet, Pere Domingo, Juan González-García, Hernando Knobel, Pablo Lázaro, Juan Carlos López, Josep M. Llibre, Fernando Lozano, José M. Miró, Daniel Podzamczer, Montserrat Tuset & Josep M. Gatell. (2016) Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas y Microbiología Clínica 34:6, pages 361-371.
Crossref
Crossref
Franco Maggiolo, Elisa Di Filippo, Daniela Valenti, Paula Serna Ortega & Annapaola Callegaro. (2016) NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes 72:1, pages 46-51.
Crossref
Crossref
Jan van Lunzen, Anton Pozniak, Jose M. Gatell, Andrea Antinori, Isabelle Klauck, Oscar Serrano, Adyb Baakili, Olayemi Osiyemi, Heather Sevinsky & Pierre-Marie Girard. (2016) Brief Report. JAIDS Journal of Acquired Immune Deficiency Syndromes 71:5, pages 538-543.
Crossref
Crossref
Josep M. Llibre, Sharon Walmsley & Josep M. Gatell. (2016) Backbones versus core agents in initial ART regimens: one game, two players. Journal of Antimicrobial Chemotherapy 71:4, pages 856-861.
Crossref
Crossref
Jean-Guy Baril, Jonathan B. Angel, M. John Gill, Joseph Gathe, Pedro Cahn, Jean van Wyk & Sharon Walmsley. (2016) Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. PLOS ONE 11:2, pages e0148231.
Crossref
Crossref
Walter Dehority, Jacobo Abadi, Andrew Wiznia & Rolando M. Viani. (2015) Use of Integrase Inhibitors in HIV-Infected Children and Adolescents. Drugs 75:13, pages 1483-1497.
Crossref
Crossref
Daniel A. Solomon & Paul E. Sax. (2015) Current state and limitations of daily oral therapy for treatment. Current Opinion in HIV and AIDS 10:4, pages 219-225.
Crossref
Crossref
A. Mondi, M. Fabbiani, N. Ciccarelli, M. Colafigli, A. D'Avino, A. Borghetti, R. Gagliardini, R. Cauda, A. De Luca & S. Di Giambenedetto. (2015) Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. Journal of Antimicrobial Chemotherapy 70:6, pages 1843-1849.
Crossref
Crossref
Antonio Javier Blasco, Josep M. Llibre, Juan Berenguer, Juan González-García, Hernando Knobel, Fernando Lozano, Daniel Podzamczer, Federico Pulido, Antonio Rivero, Montserrat Tuset, Pablo Lázaro & Josep M. Gatell. (2015) Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas y Microbiología Clínica 33:3, pages 156-165.
Crossref
Crossref
Leonardo CalzaIlaria DaneseVincenzo ColangeliGiacomo VandiRoberto ManfrediNicolò GiromettiMarco BorderiLucia AppolloniCristina PuggioliPierluigi Viale. (2014) Skeletal Muscle Toxicity in HIV-1-Infected Patients Treated with a Raltegravir-Containing Antiretroviral Therapy: A Cohort Study. AIDS Research and Human Retroviruses 30:12, pages 1162-1169.
Crossref
Crossref
Gregory M. Lucas, Michael J. Ross, Peter G. Stock, Michael G. Shlipak, Christina M. Wyatt, Samir K. Gupta, Mohamed G. Atta, Kara K. Wools-Kaloustian, Paul A. Pham, Leslie A. Bruggeman, Jeffrey L. Lennox, Patricio E. RayRobert C. Kalayjian. (2014) Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases 59:9, pages e96-e138.
Crossref
Crossref
Manuel Battegay & Luigia Elzi. (2014) Does HIV antiretroviral therapy still need its backbone?. The Lancet 384:9958, pages 1908-1910.
Crossref
Crossref
François Raffi, Abdel G Babiker, Laura Richert, Jean-Michel Molina, Elizabeth C George, Andrea Antinori, Jose R Arribas, Jesper Grarup, Fleur Hudson, Christine Schwimmer, Juliette Saillard, Cédrick Wallet, Per O Jansson, Clotilde Allavena, Remko Van Leeuwen, Jean-François Delfraissy, Stefano Vella, Geneviève Chêne & Anton Pozniak. (2014) Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. The Lancet 384:9958, pages 1942-1951.
Crossref
Crossref
T. Mesplede, N. Osman, M. Wares, P. K. Quashie, S. Hassounah, K. Anstett, Y. Han, D. N. Singhroy & M. A. Wainberg. (2014) Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. Journal of Antimicrobial Chemotherapy 69:10, pages 2733-2740.
Crossref
Crossref
Roger J. Bedimo, Henning Drechsler, Mamta Jain, James Cutrell, Song Zhang, Xilong Li, Irfan Farukhi, Rosinda Castanon, Pablo Tebas & Naim M. Maalouf. (2014) The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health. PLoS ONE 9:8, pages e106221.
Crossref
Crossref
Pierre-Marie Girard, Laurent Cotte, Joseph Gathe, Boris Renjifo, Christos Argyropoulos, Roger Trinh, Linda M Fredrick, Michael Norton & Angela Nilius. (2014) Comparison of renal changes with lopinavir/ritonavir plus raltegravir or tenofovir/emtricitabine in the PROGRESS study. Future Virology 9:8, pages 707-714.
Crossref
Crossref
Pedro Cahn, Jaime Andrade-Villanueva, José R Arribas, José M Gatell, Javier R Lama, Michael Norton, Patricia Patterson, Juan Sierra Madero, Omar Sued, Maria Inés Figueroa & Maria José Rolon. (2014) Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. The Lancet Infectious Diseases 14:7, pages 572-580.
Crossref
Crossref
Pola de la Torre, Jomy George & John D. Baxter. (2014) Nucleoside-Sparing Antiretroviral Regimens. Current Infectious Disease Reports 16:7.
Crossref
Crossref
María Inés Figueroa, Omar Sued & Pedro Cahn. (2014) What to do Next? Second-line Antiretroviral Therapy. Current Treatment Options in Infectious Diseases 6:2, pages 159-170.
Crossref
Crossref
Martin Fisher, Michael Norton, Brad Saget, Linda Fredrick & Jean van Wyk. (2014) Safety and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in patients aged <50 versus ≥50 years from randomized trials. Future Virology 9:4, pages 351-362.
Crossref
Crossref
. (2014) 5.0 What to start. HIV Medicine 15, pages 29-35.
Crossref
Crossref
Thibault Mesplède & Mark A. Wainberg. (2013) Integrase Strand Transfer Inhibitors in HIV Therapy. Infectious Diseases and Therapy 2:2, pages 83-93.
Crossref
Crossref
S. Pallikkuth, M. A. Fischl & S. Pahwa. (2013) Combination Antiretroviral Therapy With Raltegravir Leads to Rapid Immunologic Reconstitution in Treatment-Naive Patients With Chronic HIV Infection. Journal of Infectious Diseases 208:10, pages 1613-1623.
Crossref
Crossref
Antonio Javier Blasco, Josep M. Llibre, José Ramón Arribas, Vicente Boix, Bonaventura Clotet, Pere Domingo, Juan González-García, Hernando Knobel, Juan Carlos López, Fernando Lozano, José M. Miró, Daniel Podzamczer, Juan Miguel Santamaría, Montserrat Tuset, Laura Zamora, Pablo Lázaro & Josep M. Gatell. (2013) Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2013 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana. Enfermedades Infecciosas y Microbiología Clínica 31:9, pages 568-578.
Crossref
Crossref
. (2013) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013). Enfermedades Infecciosas y Microbiología Clínica 31:9, pages 602.e1-602.e98.
Crossref
Crossref
Brian A. Johns, Takashi Kawasuji & Emile J. Velthuisen. 2013. Successful Strategies for the Discovery of Antiviral Drugs. Successful Strategies for the Discovery of Antiviral Drugs
149
188
.
. (2013) Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. The Lancet 381:9883, pages 2091-2099.
Crossref
Crossref
Frederick J. Lee, Janaki Amin, Mark Bloch, Sarah L. Pett, Debbie Marriott & Andrew Carr. (2013) Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:5, pages 525-533.
Crossref
Crossref
Karen Schneider, Chidi Nwizu, Richard Kaplan, Jonathan Anderson, David P. Wilson, Sean Emery, David A. Cooper & Mark A. Boyd. (2013) The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa. PLoS ONE 8:2, pages e54435.
Crossref
Crossref
P. Monteiro, I. Perez, J. Pich, J. M. Gatell & E. Martinez. (2012) Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. Journal of Antimicrobial Chemotherapy 68:2, pages 404-408.
Crossref
Crossref
Jacques ReynesRoger TrinhFederico PulidoRuth Soto-MalaveJoseph GatheRoula QaqishMin TianLinda FredrickThomas PodsadeckiMichael NortonAngela Nilius. (2013) Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study. AIDS Research and Human Retroviruses 29:2, pages 256-265.
Crossref
Crossref
Peter Messiaen, Annemarie M. J. Wensing, Axel Fun, Monique Nijhuis, Nele Brusselaers & Linos Vandekerckhove. (2013) Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis. PLoS ONE 8:1, pages e52562.
Crossref
Crossref
Brian A. Johns, Takashi Kawasuji, Jason G. Weatherhead, Eric E. Boros, James B. Thompson, Cecilia S. Koble, Edward P. Garvey, Scott A. Foster, Jerry L. Jeffrey & Tamio Fujiwara. (2013) Naphthyridinone (NTD) integrase inhibitors: N1 Protio and methyl combination substituent effects with C3 amide groups. Bioorganic & Medicinal Chemistry Letters 23:2, pages 422-425.
Crossref
Crossref
Randall Tressler & Catherine Godfrey. (2012) NRTI Backbone in HIV Treatment. Drugs 72:16, pages 2051-2062.
Crossref
Crossref
J. Burgos, M. Crespo, V. Falco, A. Curran, J. Navarro, A. Imaz, P. Domingo, D. Podzamczer, M. G. Mateo, S. Villar, E. Van den Eynde, E. Ribera & A. Pahissa. (2012) Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy 67:10, pages 2479-2486.
Crossref
Crossref
Antonio Javier Blasco, Pablo Lázaro & Josep M. Gatell. (2012) Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial. Respuesta de los autores. Enfermedades Infecciosas y Microbiología Clínica 30:8, pages 511-512.
Crossref
Crossref
Jose E. Martín-Herrero, Javier Parrondo-García & Felipe Rodríguez-Alcántara. (2012) Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial. Enfermedades Infecciosas y Microbiología Clínica 30:8, pages 509-510.
Crossref
Crossref
Frederick J. Lee & Andrew Carr. (2012) Tolerability of HIV integrase inhibitors. Current Opinion in HIV and AIDS 7:5, pages 422-428.
Crossref
Crossref
Jeffrey L. Lennox. (2012) The use of HIV-1 integrase inhibitors in antiretroviral naive patients. Current Opinion in HIV and AIDS 7:5, pages 409-414.
Crossref
Crossref
. (2012) 5.0 What to start. HIV Medicine 13, pages 28-34.
Crossref
Crossref
. (2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). Enfermedades Infecciosas y Microbiología Clínica 30:6, pages e1-e89.
Crossref
Crossref
Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, Bonaventura Clotet, Pere Domingo, Juan González-García, Hernando Knobel, Juan Carlos López, Josep M. Llibre, Fernando Lozano, José M. Miró, Daniel Podzamczer, Juan Miguel Santamaría, Montserrat Tuset, Laura Zamora, Pablo Lázaro & Josep M. Gatell. (2012) Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana (VIH). Enfermedades Infecciosas y Microbiología Clínica 30:6, pages 283-293.
Crossref
Crossref
Judith Neumaier. (2012) Therapiestart mit zwei statt drei Substanzen. MMW - Fortschritte der Medizin 154:23-24, pages 55-55.
Crossref
Crossref
Kristina EE Rokas, P Brandon Bookstaver, Caitlin L Shamroe, S Scott Sutton, Vanessa E Millisor, Jacquelyn E Bryant & Sharon B Weissman. (2012) Role of Raltegravir in HIV-1 Management. Annals of Pharmacotherapy 46:4, pages 578-589.
Crossref
Crossref
Ángel Burgos & Cristina de Álvaro. (2012) Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial. Enfermedades Infecciosas y Microbiología Clínica 30:3, pages 167-168.
Crossref
Crossref